Iqvia Holdings Inc (NYSE:IQV) saw a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 3,450,000 shares, a decrease of 21.4% from the September 30th total of 4,390,000 shares. Based on an average trading volume of 1,350,000 shares, the days-to-cover ratio is currently 2.6 days. Currently, 2.0% of the company’s shares are short sold.

Large investors have recently added to or reduced their stakes in the business. Oppenheimer & Co. Inc. boosted its position in Iqvia by 2.0% during the 2nd quarter. Oppenheimer & Co. Inc. now owns 5,322 shares of the medical research company’s stock worth $856,000 after acquiring an additional 102 shares during the last quarter. Parallel Advisors LLC boosted its holdings in shares of Iqvia by 27.0% in the 2nd quarter. Parallel Advisors LLC now owns 512 shares of the medical research company’s stock valued at $82,000 after buying an additional 109 shares during the last quarter. APG Asset Management N.V. boosted its holdings in shares of Iqvia by 120.8% in the 2nd quarter. APG Asset Management N.V. now owns 34,000 shares of the medical research company’s stock valued at $4,804,000 after buying an additional 18,600 shares during the last quarter. Montag & Caldwell LLC boosted its holdings in shares of Iqvia by 3.3% in the 3rd quarter. Montag & Caldwell LLC now owns 2,840 shares of the medical research company’s stock valued at $424,000 after buying an additional 90 shares during the last quarter. Finally, National Asset Management Inc. boosted its holdings in shares of Iqvia by 6.6% in the 2nd quarter. National Asset Management Inc. now owns 3,787 shares of the medical research company’s stock valued at $610,000 after buying an additional 234 shares during the last quarter. 90.65% of the stock is owned by hedge funds and other institutional investors.

NYSE IQV traded up $2.13 during trading hours on Thursday, reaching $145.70. 702,593 shares of the company’s stock were exchanged, compared to its average volume of 1,289,751. The company’s 50-day moving average is $145.41 and its two-hundred day moving average is $148.39. Iqvia has a one year low of $104.90 and a one year high of $164.13. The company has a debt-to-equity ratio of 1.85, a quick ratio of 1.12 and a current ratio of 1.12. The company has a market capitalization of $27.27 billion, a price-to-earnings ratio of 28.46, a price-to-earnings-growth ratio of 1.55 and a beta of 0.87.

Iqvia (NYSE:IQV) last released its quarterly earnings results on Wednesday, October 30th. The medical research company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.03. Iqvia had a return on equity of 16.95% and a net margin of 2.24%. The firm had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.76 billion. During the same quarter in the prior year, the firm posted $1.42 EPS. The business’s revenue was up 6.7% on a year-over-year basis. Research analysts predict that Iqvia will post 5.9 earnings per share for the current fiscal year.

A number of analysts recently issued reports on IQV shares. JPMorgan Chase & Co. increased their target price on Iqvia from $160.00 to $180.00 and gave the stock an “overweight” rating in a research note on Thursday, July 25th. Wells Fargo & Co increased their target price on Iqvia from $170.00 to $178.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Credit Suisse Group increased their target price on Iqvia from $165.00 to $170.00 and gave the stock an “outperform” rating in a research note on Thursday, July 25th. Wolfe Research raised Iqvia from a “peer perform” rating to an “outperform” rating in a research note on Thursday. Finally, ValuEngine cut Iqvia from a “buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Three equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $166.46.

About Iqvia

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Article: The role of implied volatility with call option volume

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.